---
title: Skeletal Muscle Dysfunction in Heart Failure
nct_id: NCT00156234
overall_status: UNKNOWN
phase: NA
sponsor: Ullevaal University Hospital
study_type: INTERVENTIONAL
primary_condition: Heart Failure, Congestive
countries: Norway
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00156234.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00156234"
ct_last_update_post_date: 2005-09-12
last_seen_at: "2026-05-12T06:35:32.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Skeletal Muscle Dysfunction in Heart Failure

**Official Title:** Training and Congestive Heart Failure

**NCT ID:** [NCT00156234](https://clinicaltrials.gov/study/NCT00156234)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 45
- **Lead Sponsor:** Ullevaal University Hospital
- **Collaborators:** Norwegian Health Association, Norwegian School of Sport Sciences, The Research Council of Norway, University of Oslo
- **Conditions:** Heart Failure, Congestive
- **Start Date:** 2005-03
- **CT.gov Last Update:** 2005-09-12

## Brief Summary

Patients suffering from congestive heart failure report reduced exercise capacity. This skeletal muscle dysfunction is also detectable when using small muscle groups which should not put any demand on the heart.

We hypothesize that congestive heart failure has systemic effects that causes the skeletal muscle dysfunction.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 78 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Coronary Heart Failure
* Ejection fraction \<35%
* NYHA 2-3
* Spirometry FEV1 \> 80%

Exclusion Criteria:

* Cardiomyopathy
* Transplantation candidate
* Active malignancy
* Restraining skeletal-muscular disease
* Claudication in legs
* Hospitalized last 30 days due to acute ischemic episode
* Intravenous inotrope or vasodilatating drugs last 14 days prior to inclusion
* AMI last 8 weeks prior to inclusion
* Organized training last 4 months
* Smoking on daily basis last 4 months
* Creatinin \< 150microliters/liter
```

## Interventions

- **One-knee extension ergometer** (BEHAVIORAL)

## Locations (2)

- Institute for Experimental Medical Research, Oslo, Oslo, Norway — _RECRUITING_
- Norwegian School of Sport Sciences, Oslo, Oslo, Norway — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institute for experimental medical research|oslo|oslo|norway` — added _(2026-05-12)_
- `locations.norwegian school of sport sciences|oslo|oslo|norway` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00156234.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00156234*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*